← Leaderboards
William Randall Morton
University Of Washington
$9,519,887
Attributed
$9,519,887
Total exposure
49
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$10,024,887 · 50
By mechanism
P51$4,161,658 · 40
C06$3,700,000 · 3
G20$1,399,003 · 2
P40$657,813 · 3
R13$71,413 · 1
U13$35,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Geraldine Dawson$27,808,744
- Karina Lynn Walters$18,557,665
- Mary E Larimer$29,956,043
- Katharine Anthony Bradley$17,650,205
- Carey Farquhar$27,772,472
Others in their field
Top investigators on “Aids”
- Judith S. Currier · University Of California Los Angeles$495,238,846
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$400,385,565
- Lawrence Corey · Fred Hutchinson Cancer Center$397,189,786
- David Heimbrook · Leidos Biomedical Research, Inc.$340,483,893
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$316,384,846
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$310,253,675
Research focus
AidsMammaliaImmunologyInflammationVirusCommunicable DiseasesLymphatic SystemModel Design /DevelopmentVaccinesAnimal ColonyPrimatesBiotechnologyClinical ResearchPongidaeVeterinary ScienceSexually Transmitted DiseasesCatalogsTissue Resource /RegistryInformation SystemsPostmortemPsychologyHiv InfectionsSociology /AnthropologyHuman Immunodeficiency Virus
Grant awards (62)
IN VIVO EVALUATION OF PRIMATE LENTIVIRUSES II$175,831
P51 · FY2005 · RR
LONG-TERM SURVIVORS OF SIV/HIV INFECTION$175,831
P51 · FY2005 · RR
SIMIAN VACCINE EVALUATION UNIT (SVEU)$175,831
P51 · FY2005 · RR
CELL MEDIATED IMMUNITY TO SIV$149,425
P51 · FY2005 · RR
PRIMATE SUPPLY INFORMATION CLEARINGHOUSE: AIDS$21,328
P40 · FY2005 · RR
PRIMATE SUPPLY INFORMATION CLEARINGHOUSE$11,485
P40 · FY2005 · RR
EXTRAMURAL RES FACIL IMPROVEMENT PROGRAM PROJ*: AIDS$1,480,000
C06 · FY2004 · RR
EXTRAMURAL RES FACIL IMPROVEMENT PROGRAM PROJ*:EMERGING INFECTIOUS DISEASES$1,110,000
C06 · FY2004 · RR
EXTRAMURAL RES FACIL IMPROVEMENT PROGRAM PROJ*: BIODEFENSE$1,110,000
C06 · FY2004 · RR
LONG-TERM SURVIVORS OF SIV/HIV INFECTION$161,398
P51 · FY2004 · RR
IN VIVO EVALUATION OF PRIMATE LENTIVIRUSES$161,398
P51 · FY2004 · RR
SIMIAN VACCINE EVALUATION UNIT (SVEU)$161,398
P51 · FY2004 · RR
WANPRC SEMINAR SERIES$161,398
P51 · FY2004 · RR
RESEARCH REVIEW COMMITTEE$78,235
P51 · FY2004 · RR
PRIMATE SUPPLY INFORMATION CLEARINGHOUSE: AIDS$78,000
P40 · FY2004 · RR
PRIMATE SUPPLY INFORMATION CLEARINGHOUSE$42,000
P40 · FY2004 · RR
ABSL2/3 EQUIPMENT$699,384
G20 · FY2003 · RR
IN VIVO ENHANCEMENT OF HIV-1 IN MACACCA NEMESTRINA$189,414
P51 · FY2003 · RR
EVALUATION OF VSV-G PSEUDOTYPED HIV-2 VECTORS$189,414
P51 · FY2003 · RR
LONG-TERM SURVIVORS OF SIV/HIV INFECTION$189,414
P51 · FY2003 · RR
CELL MEDIATED IMMUNITY$189,414
P51 · FY2003 · RR
WANPRC SEMINAR SERIES$189,414
P51 · FY2003 · RR
SIMIAN VACCINE EVALUATION UNIT (SVEU)$189,414
P51 · FY2003 · RR
IN VIVO EVALUATION OF PRIMATE LENTIVIRUSES$189,414
P51 · FY2003 · RR
PRIMATE INFORMATION CLEARINGHOUSE$120,000
P40 · FY2003 · RR
BLUE RIBBON ADVISORY COMMITTEE$90,834
P51 · FY2003 · RR
EXECUTIVE ADVISORY COMMITTEE$90,834
P51 · FY2003 · RR
21ST ANNUAL SYMPOSIUM ON NHP MODELS FOR AIDS$71,413
R13 · FY2003 · RR
RESEARCH REVIEW COMMITTEE$2,012
P51 · FY2003 · RR
PRIMATE INFORMATION CLEARINGHOUSE$145,000
P40 · FY2002 · RR
WaRPRC AIDS EQUIPMENT-3$699,619
G20 · FY2001 · RR
PRIMATE INFORMATION CLEARINGHOUSE$120,000
P40 · FY2001 · RR
Workshop on Nonhuman Primate Genomics$35,000
U13 · FY2001 · RR
ENVELOPE SPECIFIC IMMUNITY AGAINST VARIOUS SIV CHALLENGE CONDITIONS$0
P51 · FY2001 · RR
INTERNATIONAL PRIMATE CENTER: RUSSIA: M NEMESTRINA &PAPIO ANUBIS CYNOEPHALUS$0
P51 · FY2001 · RR
INDONESIAN PROGRAM: PROVIDE AIDS RESEARCH SIV FREE BREEDING COLONIES$0
P51 · FY2001 · RR
PRIMATE SUPPLY INFORMATION CLEARINGHOUSE (PSIC)$0
P51 · FY2001 · RR
INFECTION OF M NEMESTRINA W/ HIV 2 BY ORAL ADMINISTRATION$0
P51 · FY2001 · RR
T CELL LYMPHOMA IN MACACA NEMESTRINA$0
P51 · FY2001 · RR
IN VIVO EVALUATION OF PRIMATE LENTIVIRUSES IN M NEMESTRINA$0
P51 · FY2001 · RR
IN VIVO ENHANCEMENT OF HIV 1 IN M NEMESTRINA$0
P51 · FY2001 · RR
TITRATION OF SIVMNE USING INTRAVAGINAL INOCULATION$0
P51 · FY2001 · RR
LONG TERM SURVIVORS OF SIV &HIV INFECTION$0
P51 · FY2001 · RR
IMMUNOGENICITY OF ENVELOPE AND/OR CORE ANTIGENS OF HIV 1 LAI$0
P51 · FY2001 · RR
RECOMBINANT VACCINIA VIRUSES EXPRESSING ENV AND/OR CORE ANTIGENS OF SIVMNE$0
P51 · FY2001 · RR
IMMUNOGENICITY OF RECOMBINANT VACCINIA VIRUS EXPRESSING ENV GLYCOPROTEINS$0
P51 · FY2001 · RR
ALLOIMMUNIZATION OF MACACA NEMESTRINA W/ MHC CLASS II ANTIGENS$0
P51 · FY2001 · RR
IMMUNIZATION W/ DNA CODING$0
P51 · FY2001 · RR
SHIV CHALLENGE &DEVELOPMENT OF SHIV229 MACAQUE MODEL$0
P51 · FY2001 · RR
YILMA SIV VACCINIA VACCINE TRIAL$0
P51 · FY2001 · RR
ENVELOPE SPECIFIC IMMUNITY AGAINST DIFFERENT SIV CHALLENGE CONDITIONS$132,406
P51 · FY2000 · RR
ALLOIMMUNIZATION OF MACACA NEMESTRINA W/ MHC CLASS II ANTIGENS: SIV$132,406
P51 · FY2000 · RR
VSV G PSEUDOTYPED HIV 2 VECTORS$132,406
P51 · FY2000 · RR
DEPLETION OF CD8+ CELLS IN HIV 2 INFECTED MACAQUES PRE TREATED W/ D4T$132,406
P51 · FY2000 · RR
IN VIVO INFECTIVITY &PATHOGENICITY OF MOLECULAR CLONES OF HIV 2287$132,406
P51 · FY2000 · RR
IMMUNOGENICITY OF ENVELOPE AND/OR CORE ANTIGENS OF HIV 1 LAI$132,406
P51 · FY2000 · RR
LONG TERM SURVIVORS OF SIV &HIV INFECTION$132,406
P51 · FY2000 · RR
IMMUNIZATION W/ DNA CODING: SIV$132,406
P51 · FY2000 · RR
PRIMATE INFORMATION CLEARINGHOUSE$120,000
P40 · FY2000 · RR
INDONESIAN PROGRAM: PROVIDE AIDS RESEARCH SIV FREE BREEDING COLONIES$119,933
P51 · FY2000 · RR
PRIMATE SUPPLY INFORMATION CLEARINGHOUSE (PSIC)$52,589
P51 · FY2000 · RR
RUSSIAN PROGRAM: PROVIDE PAPIO ANUBIS (BABOON)$19,565
P51 · FY2000 · RR